Tesamorelin Will Get Advisory Committee Review For Treatment Of HIV-Drug Side Effect
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck-Serono/Theratechnologies' Egrifta would be a first-in-class product for lipodystrophy, which sponsors say is a $1.3 billion market.